HC Wainwright Reaffirms “Buy” Rating for Aptose Biosciences (NASDAQ:APTO)

Aptose Biosciences (NASDAQ:APTO) (TSE:APS)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $2.00 target price on the biotechnology company’s stock.

Separately, StockNews.com began coverage on shares of Aptose Biosciences in a research report on Friday, November 29th. They set a “hold” rating on the stock.

Aptose Biosciences Stock Performance

APTO opened at $0.19 on Tuesday. The company has a fifty day moving average price of $0.34 and a two-hundred day moving average price of $0.54. Aptose Biosciences has a 52 week low of $0.13 and a 52 week high of $2.91. The firm has a market capitalization of $3.40 million, a PE ratio of -0.06 and a beta of 1.06.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC acquired a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned about 9.46% of Aptose Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.